Michigan Pharmacy and Therapeutics Committee September 11, Minutes

Transcription

1 Michigan Pharmacy and Therapeutics Committee September 11, 2018 Minutes Attendees: Vickie Tutag Lehr, Brian Peltz, Jayne Courts, Rony Foumia, Andrew Mac, Andrew Adair, Margo Farber, David Neff, Brad Uren Absent: Anthony Ognjan, Venkat Rao The MDHHS P & T committee was called to order at 6:00 pm by the chair, Dr. Vicki Tutag Lehr. The agenda was reviewed and accepted. Introductions were made, and quorum established. Conflict of interest statement was reviewed. Annual attestations were signed. None of the members had COI to report. The review of the June 7, 2018 meeting minutes was tabled. They will be reviewed at the December meeting. P & T Business: The Committee was provided Policy Updates, Legislative Updates, Pipeline Drugs and New Indications and general clinical updates. Dr. Neff announced that Dr. Venkat Rao will be leaving the Committee because he has been appointed to the Board of Medicine. New Drug Review: The committee reviewed the following new drugs and approved that the following new agents reviewed be added to the formulary as non-preferred as follows: 1. BONJESTA (doxylamine succinate and pyridoxine hydrochloride) extended-release tablets [Not a PDL class - Add to MPPL with PA required] 2. JYNARQUE (tolvaptan) tablets - [Not a PDL class - Add to MPPL with PA required] 3. LONHALA MAGNAIR (glycopyrrolate) inhalation solution - [PDL class: Anticholinergic Agents - Long Acting; non-preferred] 4. RHOPRESSA (netarsudil) ophthalmic solution 0.02% - [PDL class: Glaucoma Rho Kinase Inhibitor; nonpreferred] 5. ZYPITAMAG (pitavastatin) tablets [PDL class: Lipotropics- Statins; non-preferred] 1

2 Preferred Drug List Classes: A review of the following Preferred Drug Classes was performed, and the following actions were taken. Diabetes: 1. Amylin Analogs 2. Incretin Mimetics a. Move Bydureon (exenatide) Bcise to non-preferred. 3. Incretin Mimetic Combinations 4. Insulins: Basal 5. Insulins: Rapid Acting 6. Insulin Mixes a. Move Humalog 200 U/ml Kwikpen to non-preferred b. Move Novolin 70/30 vial to non-preferred c. Move Humulin 70/30 Pen to non-preferred 7. Insulins: Traditional a. Move Humulin N pens to non-preferred 8. Oral Hypoglycemics: Alpha-Glucosidase Inhibitors 9. Oral Hypoglycemics: Biguanides 10. Oral Hypoglycemics: Combinations a. Move Glyxambi (empagliflozin/linagliptin) to preferred 11. Oral Hypoglycemics: Dopamine Receptor Agonists 12. Oral Hypoglycemics: DPP4 Inhibitors 13. Oral Hypoglycemics: Meglitinides 14. Oral Hypoglycemics: 2 nd Generation Sulfonylureas 2

3 15. Oral Hypoglycemics: SGLT2 Inhibitors 16. Oral Hypoglycemics: Thiazolidinediones Gastrointestinal: 1. Antiemetics 2. Bile Salts 3. GI Motility, Chronic 4. H. pylori Treatment 5. Pancreatic Enzymes 6. Progestins for Cachexia 7. Proton Pump Inhibitors 8. Ulcerative Colitis Miscellaneous: 1. Biologic Immunomodulators a. Agents to Treat Rheumatoid Arthritis b. Agents to Treat Ankylosing Spondylitis c. Agents to Treat Juvenile Idiopathic Arthritis d. Agents to Treat Plaque Psoriasis i. Move Cosentyx (secukinumab) to preferred e. Agents to Treat Psoriatic Arthritis i. Move Cosentyx (secukinumab) to preferred f. Agents to Treat Crohn s Disease g. Agents to Treat Ulcerative Colitis. 3

4 2. Androgenic Agents (topical) 3. BPH Agents 4. Colony Stimulating Factors new class a. Add the following as preferred i. Neupogen (filgrastim) i. Neulasta (pegfilgrastim) b. Add the following as non-preferred i. Granix (tbo-filgrastim) ii. Leukine (sargramostim) iii. Zarxio (filgrastim-sndz) 5. Electrolyte Depleters 6. Epinephrine Injectable 7. Growth Hormones 8. Hematopoietic Agents 9. Osteoporosis Agents: Bisphosphonates 10. Osteoporosis Agents: Other 11. Osteoporosis Agents: SERMS 12. Progestational Agents new class a. Add the following as preferred i. medroxyprogesterone (oral) ii. progesterone (oral) iii. norethindrone (oral) iv. Makena (hydroxyprogesterone caproate) - (intramuscular and subcutaneous) b. Add the following as non-preferred i. Aygestin (oral) ii. Crinone (vaginal) iii. Depo-Provera (injection) iv. hydroxyprogesterone caproate (intramuscular) v. progesterone (intramuscular) 4

5 vi. Prometrium (oral) vii. Provera (medroxyprogesterone) (oral) 13. Urinary Tract Antispasmodics Public Comments: 1. Jeff Martin, PharmD, Amgen, re. etanercept (Enbrel mini), erenumab-aooe (Aimovig) 2. Ndidi Yaucher, PharmD, Novartis, re. Gilenya 3. Jean Ritter, Retrophin Inc., re. Thiola 4. Mohammedi Savliwala, MD, Independent physician practice, re. Atopic Dermatitis and Access 5. Ashley Polce, PharmD, AbbVie, re. Orilissa 6. Kevin Townsend, PharmD, Pfizer, re. Eucrisa, Atopic Dermatitis 7. Justin Barnes, PhD, Tris Medical Science, re. Dyanavel XR 8. Manoj Mohan, D.O., Okemos Allergy Center, re. Eucrisa Next Meeting: Tuesday, December 11, :00 PM Location: Kellogg Center, MSU 5